A nasal antiviral created by researchers blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus, including recent variants. The compound in the spray is designed to prevent the new coronavirus from entering host cells.
The antiviral lipopeptide is inexpensive to produce, has a long shelf life, and does not require refrigeration. These features make it stand out from other antiviral approaches under development, including many monoclonal antibodies. The new nasal lipopeptide could be ideal for halting the spread of COVID in the United States and globally; the transportable and stable compound could be especially key in rural, low-income, and hard-to-reach populations. The study is published in Science.
Ferrets are often used in studies of respiratory diseases because the lungs of these animals and humans are similar. Ferrets are highly susceptible to infection with SARS-CoV-2, and the virus spreads easily from ferret to ferret.
In this study 100% of the untreated ferrets were infected by their virus-shedding cagemates, approximating a setting like sharing a bed or close living conditions for people.
The authors have previously created similar lipopeptides--small proteins joined to a cholesterol or tocopherol molecule--to prevent infection of cells by other viruses, including measles, parainfluenza, and Nipah viruses. These anti-viral compounds have been challenging to bring to human trials, in large part because the infections they prevent are most prevalent or serious in low-income contexts.
When SARS-CoV-2 emerged, the researchers adapted their designs to the new coronavirus. "One lesson we want to stress is the importance of applying basic science to develop treatments for viruses that affect human populations globally," the authors say. "The fruits of our earlier research led to our rapid application of the methods to COVID-19."
A paper describing a first generation of the compound and its effect in a 3D model of the human lung first appeared in the journal mBio. In this human lung model, the compound was able to extinguish an initial infection, prevent spread of the virus within the lung, and was not at all toxic to the airway cells.
The lipopeptides work by preventing a virus from fusing with its host's cell membrane, a necessary step that enveloped viruses, including SARS-CoV-2, use to infect cells. To fuse, the new coronavirus unfolds its spike protein before contracting into a compact bundle that drives the fusion.
The compound recognizes the SARS-CoV-2 spike, wedges itself into the unfolded region, and prevents the spike protein from adopting the compact shape necessary for fusion.
In the ferret experiments at Erasmus, the lipopeptide was delivered into the noses of six ferrets. Pairs of treated ferrets were then housed with two control ferrets that received a saline nasal spray and one ferret infected with SARS-CoV-2.
After 24 hours of intense direct contact among the ferrets, tests revealed that none of the treated ferrets caught the virus from their infected cagemate and their viral load was precisely zero, while all of the control animals were highly infected.
Public health officials are concerned about the emergence of several SARS-CoV-2 variants, which appear to be more transmissible and deadly, and could be more adept at evading the antibodies generated by current therapies and vaccines available.
The authors tested the lipopeptide on cells infected with a range of SARS-CoV-2 variants, including B.1.1.7 and B.1.351, and found that the compound prevented the spike protein of all variants from fusing with the cell membrane as effectively as the dominant strain.
The authors propose these peptides could be used in any situation where an uninfected person would be exposed, whether in a household, school, health care setting, or community.
"Even in an ideal scenario with large segments of the population vaccinated--and with full trust in and compliance with vaccination procedures--these antivirals will form an important complement to protect individuals and control transmission," the authors say. People who cannot be vaccinated or do not develop immunity will particularly benefit from the spray.
The antiviral is easily administered and, based on the scientists' experience with other respiratory viruses, protection would be immediate and last for at least 24 hours.
The scientists are conducting advanced studies on transmission in animal models and on production and formulation of the peptide. They hope to bring this preventative approach to human clinical trials soon, with the ultimate goal of deploying the therapy to help contain transmission during this pandemic and to support preparedness for future emerging strains and pandemics.
https://www.cuimc.columbia.edu/news/could-nasal-spray-prevent-coronavirus-transmission
https://science.sciencemag.org/content/early/2021/02/16/science.abf4896
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fintranasal-fusion&filter=22
Nasal peptide and viral transmission
- 2,111 views
- Added
Edited
Latest News
New origin of deep brain waves
By newseditor
Posted 17 Apr
Starving cells hijack prote…
By newseditor
Posted 17 Apr
Miniature battery-free epid…
By newseditor
Posted 17 Apr
Molecular causes of differe…
By newseditor
Posted 16 Apr
Cell's 'garbage disposal' h…
By newseditor
Posted 16 Apr
Other Top Stories
Injected peptide modifies gene in CNS
Read more
DNA methylation signatures in Alzheimer's specific brain cells
Read more
Myelination defect in Huntington disease
Read more
Is your blood type linked to your risk of stroke before age 60?
Read more
Prefrontal-habenular microstructural impairments in human cocaine a…
Read more
Protocols
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Modular dual-color BiAD sen…
By newseditor
Posted 31 Mar
Publications
The immunobiology of herpes…
By newseditor
Posted 17 Apr
Circulating microbiome DNA…
By newseditor
Posted 17 Apr
Spindle oscillations in com…
By newseditor
Posted 17 Apr
Oligodendroglial macroautop…
By newseditor
Posted 17 Apr
COPII with ALG2 and ESCRTs…
By newseditor
Posted 17 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar